U.S., May 15 -- ClinicalTrials.gov registry received information related to the study (NCT06969781) titled 'MWA With or Without Furmonertinib for Early-Stage Non-Small Cell Lung Cancer' on April 29.
Brief Summary: This is a single-center randomized trial that investigates microwave ablation (MWA) combined with EGFR-TKI therapy in 120 early-stage NSCLC patients (T1-T2N0M0, EGFR-mutant) unsuitable for standard treatments. Participants are stratified by tumor characteristics and randomized equally to MWA alone, MWA-TKI concurrent, or TKI induction followed by MWA-TKI, assessing disease-free survival, overall survival, and safety outcomes. The study compares the clinical benefits and optimal sequencing of local ablation with targeted therapy i...